CELL REP MED 润色咨询

CELL REPORTS MEDICINE

出版年份:暂无数据 年文章数:290 投稿命中率: 开通期刊会员,数据随心看

出版周期:暂无数据 自引率:暂无数据 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2145282, encodeId=6244214528220, content=审稿速度:4.0<br>偏重的研究方向:临床医学<br>经验分享:cell新子刊,看近期的文章质量,往20分去的。有幸中了一篇,历时7个月,本人肿瘤方向,主要做的临床样本和机制。前期慢的都想溜了,还好耐心等下去了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48ef2508535, createdName=yo3333, createdTime=Wed Jun 28 22:27:14 CST 2023, time=2023-06-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2138810, encodeId=3dbf2138810b5, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤免疫<br>经验分享:首个影响因子很高,仔细分析发现,引用次数前十的都是新冠相关的研究,预计最近两年的影响因子将持续下滑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=DDPP, createdTime=Wed May 24 13:49:22 CST 2023, time=2023-05-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2181986, encodeId=5e5b21819861b, content=想问一下,pre-accept之后大概多久发proof啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64935318954, createdName=尤文化, createdTime=Tue Jan 16 15:46:02 CST 2024, time=2024-01-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2177325, encodeId=e95a21e732597, content=审稿速度:24.0 | 投稿命中率:5.0<br>偏重的研究方向:肿瘤<br>经验分享:投稿1年,数次修回,暂无进展。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7d361735891, createdName=ITALIAN, createdTime=Tue Dec 26 16:46:22 CST 2023, time=2023-12-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2173652, encodeId=c0a321e36528e, content=cell转投,转投三天了,还没分配编辑和稿号,这正常吗?请问大佬们有没有遇到过这样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ab745477244, createdName=xiaozou_up20, createdTime=Fri Dec 08 09:10:48 CST 2023, time=2023-12-08, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2169679, encodeId=968821696e98f, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59f79071994, createdName=ms7000000914996124, createdTime=Mon Nov 20 10:11:48 CST 2023, time=2023-11-20, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2118459, encodeId=00542118459f1, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:请教下,修回后一般多久有消息啊?还送外审么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a302426205, createdName=123a7f4dm47暂无昵称, createdTime=Thu Mar 09 10:31:00 CST 2023, time=2023-03-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1213677, encodeId=475b12136e7ee, content=审稿两个月了,希望能给个修回。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=27, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210104/1a4d3d11af7842afadd172a4a59b32f9/66b07e825e8e4455b5099c678c51e0c6.jpg, createdBy=ab332214260, createdName=susu2019, createdTime=Sat Apr 23 15:06:58 CST 2022, time=2022-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145332, encodeId=8473214533219, content=2023年14.3分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:40:51 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2129432, encodeId=85e32129432bc, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=682b8647575, createdName=ms5000001932404434, createdTime=Sun Apr 30 15:27:39 CST 2023, time=2023-04-30, status=1, ipAttribution=上海)]
    2023-06-28 yo3333 来自上海

    审稿速度:4.0
    偏重的研究方向:临床医学
    经验分享:cell新子刊,看近期的文章质量,往20分去的。有幸中了一篇,历时7个月,本人肿瘤方向,主要做的临床样本和机制。前期慢的都想溜了,还好耐心等下去了

    9

    展开9条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2145282, encodeId=6244214528220, content=审稿速度:4.0<br>偏重的研究方向:临床医学<br>经验分享:cell新子刊,看近期的文章质量,往20分去的。有幸中了一篇,历时7个月,本人肿瘤方向,主要做的临床样本和机制。前期慢的都想溜了,还好耐心等下去了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48ef2508535, createdName=yo3333, createdTime=Wed Jun 28 22:27:14 CST 2023, time=2023-06-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2138810, encodeId=3dbf2138810b5, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤免疫<br>经验分享:首个影响因子很高,仔细分析发现,引用次数前十的都是新冠相关的研究,预计最近两年的影响因子将持续下滑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=DDPP, createdTime=Wed May 24 13:49:22 CST 2023, time=2023-05-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2181986, encodeId=5e5b21819861b, content=想问一下,pre-accept之后大概多久发proof啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64935318954, createdName=尤文化, createdTime=Tue Jan 16 15:46:02 CST 2024, time=2024-01-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2177325, encodeId=e95a21e732597, content=审稿速度:24.0 | 投稿命中率:5.0<br>偏重的研究方向:肿瘤<br>经验分享:投稿1年,数次修回,暂无进展。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7d361735891, createdName=ITALIAN, createdTime=Tue Dec 26 16:46:22 CST 2023, time=2023-12-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2173652, encodeId=c0a321e36528e, content=cell转投,转投三天了,还没分配编辑和稿号,这正常吗?请问大佬们有没有遇到过这样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ab745477244, createdName=xiaozou_up20, createdTime=Fri Dec 08 09:10:48 CST 2023, time=2023-12-08, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2169679, encodeId=968821696e98f, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59f79071994, createdName=ms7000000914996124, createdTime=Mon Nov 20 10:11:48 CST 2023, time=2023-11-20, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2118459, encodeId=00542118459f1, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:请教下,修回后一般多久有消息啊?还送外审么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a302426205, createdName=123a7f4dm47暂无昵称, createdTime=Thu Mar 09 10:31:00 CST 2023, time=2023-03-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1213677, encodeId=475b12136e7ee, content=审稿两个月了,希望能给个修回。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=27, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210104/1a4d3d11af7842afadd172a4a59b32f9/66b07e825e8e4455b5099c678c51e0c6.jpg, createdBy=ab332214260, createdName=susu2019, createdTime=Sat Apr 23 15:06:58 CST 2022, time=2022-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145332, encodeId=8473214533219, content=2023年14.3分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:40:51 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2129432, encodeId=85e32129432bc, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=682b8647575, createdName=ms5000001932404434, createdTime=Sun Apr 30 15:27:39 CST 2023, time=2023-04-30, status=1, ipAttribution=上海)]
    2023-05-24 DDPP 来自广东省

    审稿速度:2.0 | 投稿命中率:25.0
    偏重的研究方向:肿瘤免疫
    经验分享:首个影响因子很高,仔细分析发现,引用次数前十的都是新冠相关的研究,预计最近两年的影响因子将持续下滑。

    5

    展开5条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2145282, encodeId=6244214528220, content=审稿速度:4.0<br>偏重的研究方向:临床医学<br>经验分享:cell新子刊,看近期的文章质量,往20分去的。有幸中了一篇,历时7个月,本人肿瘤方向,主要做的临床样本和机制。前期慢的都想溜了,还好耐心等下去了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48ef2508535, createdName=yo3333, createdTime=Wed Jun 28 22:27:14 CST 2023, time=2023-06-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2138810, encodeId=3dbf2138810b5, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤免疫<br>经验分享:首个影响因子很高,仔细分析发现,引用次数前十的都是新冠相关的研究,预计最近两年的影响因子将持续下滑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=DDPP, createdTime=Wed May 24 13:49:22 CST 2023, time=2023-05-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2181986, encodeId=5e5b21819861b, content=想问一下,pre-accept之后大概多久发proof啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64935318954, createdName=尤文化, createdTime=Tue Jan 16 15:46:02 CST 2024, time=2024-01-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2177325, encodeId=e95a21e732597, content=审稿速度:24.0 | 投稿命中率:5.0<br>偏重的研究方向:肿瘤<br>经验分享:投稿1年,数次修回,暂无进展。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7d361735891, createdName=ITALIAN, createdTime=Tue Dec 26 16:46:22 CST 2023, time=2023-12-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2173652, encodeId=c0a321e36528e, content=cell转投,转投三天了,还没分配编辑和稿号,这正常吗?请问大佬们有没有遇到过这样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ab745477244, createdName=xiaozou_up20, createdTime=Fri Dec 08 09:10:48 CST 2023, time=2023-12-08, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2169679, encodeId=968821696e98f, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59f79071994, createdName=ms7000000914996124, createdTime=Mon Nov 20 10:11:48 CST 2023, time=2023-11-20, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2118459, encodeId=00542118459f1, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:请教下,修回后一般多久有消息啊?还送外审么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a302426205, createdName=123a7f4dm47暂无昵称, createdTime=Thu Mar 09 10:31:00 CST 2023, time=2023-03-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1213677, encodeId=475b12136e7ee, content=审稿两个月了,希望能给个修回。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=27, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210104/1a4d3d11af7842afadd172a4a59b32f9/66b07e825e8e4455b5099c678c51e0c6.jpg, createdBy=ab332214260, createdName=susu2019, createdTime=Sat Apr 23 15:06:58 CST 2022, time=2022-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145332, encodeId=8473214533219, content=2023年14.3分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:40:51 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2129432, encodeId=85e32129432bc, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=682b8647575, createdName=ms5000001932404434, createdTime=Sun Apr 30 15:27:39 CST 2023, time=2023-04-30, status=1, ipAttribution=上海)]
    2024-01-16 尤文化 来自江苏省

    想问一下,pre-accept之后大概多久发proof啊?

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2145282, encodeId=6244214528220, content=审稿速度:4.0<br>偏重的研究方向:临床医学<br>经验分享:cell新子刊,看近期的文章质量,往20分去的。有幸中了一篇,历时7个月,本人肿瘤方向,主要做的临床样本和机制。前期慢的都想溜了,还好耐心等下去了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48ef2508535, createdName=yo3333, createdTime=Wed Jun 28 22:27:14 CST 2023, time=2023-06-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2138810, encodeId=3dbf2138810b5, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤免疫<br>经验分享:首个影响因子很高,仔细分析发现,引用次数前十的都是新冠相关的研究,预计最近两年的影响因子将持续下滑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=DDPP, createdTime=Wed May 24 13:49:22 CST 2023, time=2023-05-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2181986, encodeId=5e5b21819861b, content=想问一下,pre-accept之后大概多久发proof啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64935318954, createdName=尤文化, createdTime=Tue Jan 16 15:46:02 CST 2024, time=2024-01-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2177325, encodeId=e95a21e732597, content=审稿速度:24.0 | 投稿命中率:5.0<br>偏重的研究方向:肿瘤<br>经验分享:投稿1年,数次修回,暂无进展。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7d361735891, createdName=ITALIAN, createdTime=Tue Dec 26 16:46:22 CST 2023, time=2023-12-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2173652, encodeId=c0a321e36528e, content=cell转投,转投三天了,还没分配编辑和稿号,这正常吗?请问大佬们有没有遇到过这样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ab745477244, createdName=xiaozou_up20, createdTime=Fri Dec 08 09:10:48 CST 2023, time=2023-12-08, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2169679, encodeId=968821696e98f, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59f79071994, createdName=ms7000000914996124, createdTime=Mon Nov 20 10:11:48 CST 2023, time=2023-11-20, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2118459, encodeId=00542118459f1, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:请教下,修回后一般多久有消息啊?还送外审么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a302426205, createdName=123a7f4dm47暂无昵称, createdTime=Thu Mar 09 10:31:00 CST 2023, time=2023-03-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1213677, encodeId=475b12136e7ee, content=审稿两个月了,希望能给个修回。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=27, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210104/1a4d3d11af7842afadd172a4a59b32f9/66b07e825e8e4455b5099c678c51e0c6.jpg, createdBy=ab332214260, createdName=susu2019, createdTime=Sat Apr 23 15:06:58 CST 2022, time=2022-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145332, encodeId=8473214533219, content=2023年14.3分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:40:51 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2129432, encodeId=85e32129432bc, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=682b8647575, createdName=ms5000001932404434, createdTime=Sun Apr 30 15:27:39 CST 2023, time=2023-04-30, status=1, ipAttribution=上海)]
    2023-12-26 ITALIAN 来自上海

    审稿速度:24.0 | 投稿命中率:5.0
    偏重的研究方向:肿瘤
    经验分享:投稿1年,数次修回,暂无进展。

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2145282, encodeId=6244214528220, content=审稿速度:4.0<br>偏重的研究方向:临床医学<br>经验分享:cell新子刊,看近期的文章质量,往20分去的。有幸中了一篇,历时7个月,本人肿瘤方向,主要做的临床样本和机制。前期慢的都想溜了,还好耐心等下去了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48ef2508535, createdName=yo3333, createdTime=Wed Jun 28 22:27:14 CST 2023, time=2023-06-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2138810, encodeId=3dbf2138810b5, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤免疫<br>经验分享:首个影响因子很高,仔细分析发现,引用次数前十的都是新冠相关的研究,预计最近两年的影响因子将持续下滑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=DDPP, createdTime=Wed May 24 13:49:22 CST 2023, time=2023-05-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2181986, encodeId=5e5b21819861b, content=想问一下,pre-accept之后大概多久发proof啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64935318954, createdName=尤文化, createdTime=Tue Jan 16 15:46:02 CST 2024, time=2024-01-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2177325, encodeId=e95a21e732597, content=审稿速度:24.0 | 投稿命中率:5.0<br>偏重的研究方向:肿瘤<br>经验分享:投稿1年,数次修回,暂无进展。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7d361735891, createdName=ITALIAN, createdTime=Tue Dec 26 16:46:22 CST 2023, time=2023-12-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2173652, encodeId=c0a321e36528e, content=cell转投,转投三天了,还没分配编辑和稿号,这正常吗?请问大佬们有没有遇到过这样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ab745477244, createdName=xiaozou_up20, createdTime=Fri Dec 08 09:10:48 CST 2023, time=2023-12-08, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2169679, encodeId=968821696e98f, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59f79071994, createdName=ms7000000914996124, createdTime=Mon Nov 20 10:11:48 CST 2023, time=2023-11-20, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2118459, encodeId=00542118459f1, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:请教下,修回后一般多久有消息啊?还送外审么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a302426205, createdName=123a7f4dm47暂无昵称, createdTime=Thu Mar 09 10:31:00 CST 2023, time=2023-03-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1213677, encodeId=475b12136e7ee, content=审稿两个月了,希望能给个修回。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=27, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210104/1a4d3d11af7842afadd172a4a59b32f9/66b07e825e8e4455b5099c678c51e0c6.jpg, createdBy=ab332214260, createdName=susu2019, createdTime=Sat Apr 23 15:06:58 CST 2022, time=2022-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145332, encodeId=8473214533219, content=2023年14.3分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:40:51 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2129432, encodeId=85e32129432bc, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=682b8647575, createdName=ms5000001932404434, createdTime=Sun Apr 30 15:27:39 CST 2023, time=2023-04-30, status=1, ipAttribution=上海)]
    2023-12-08 xiaozou_up20 来自广西

    cell转投,转投三天了,还没分配编辑和稿号,这正常吗?请问大佬们有没有遇到过这样

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2145282, encodeId=6244214528220, content=审稿速度:4.0<br>偏重的研究方向:临床医学<br>经验分享:cell新子刊,看近期的文章质量,往20分去的。有幸中了一篇,历时7个月,本人肿瘤方向,主要做的临床样本和机制。前期慢的都想溜了,还好耐心等下去了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48ef2508535, createdName=yo3333, createdTime=Wed Jun 28 22:27:14 CST 2023, time=2023-06-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2138810, encodeId=3dbf2138810b5, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤免疫<br>经验分享:首个影响因子很高,仔细分析发现,引用次数前十的都是新冠相关的研究,预计最近两年的影响因子将持续下滑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=DDPP, createdTime=Wed May 24 13:49:22 CST 2023, time=2023-05-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2181986, encodeId=5e5b21819861b, content=想问一下,pre-accept之后大概多久发proof啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64935318954, createdName=尤文化, createdTime=Tue Jan 16 15:46:02 CST 2024, time=2024-01-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2177325, encodeId=e95a21e732597, content=审稿速度:24.0 | 投稿命中率:5.0<br>偏重的研究方向:肿瘤<br>经验分享:投稿1年,数次修回,暂无进展。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7d361735891, createdName=ITALIAN, createdTime=Tue Dec 26 16:46:22 CST 2023, time=2023-12-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2173652, encodeId=c0a321e36528e, content=cell转投,转投三天了,还没分配编辑和稿号,这正常吗?请问大佬们有没有遇到过这样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ab745477244, createdName=xiaozou_up20, createdTime=Fri Dec 08 09:10:48 CST 2023, time=2023-12-08, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2169679, encodeId=968821696e98f, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59f79071994, createdName=ms7000000914996124, createdTime=Mon Nov 20 10:11:48 CST 2023, time=2023-11-20, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2118459, encodeId=00542118459f1, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:请教下,修回后一般多久有消息啊?还送外审么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a302426205, createdName=123a7f4dm47暂无昵称, createdTime=Thu Mar 09 10:31:00 CST 2023, time=2023-03-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1213677, encodeId=475b12136e7ee, content=审稿两个月了,希望能给个修回。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=27, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210104/1a4d3d11af7842afadd172a4a59b32f9/66b07e825e8e4455b5099c678c51e0c6.jpg, createdBy=ab332214260, createdName=susu2019, createdTime=Sat Apr 23 15:06:58 CST 2022, time=2022-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145332, encodeId=8473214533219, content=2023年14.3分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:40:51 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2129432, encodeId=85e32129432bc, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=682b8647575, createdName=ms5000001932404434, createdTime=Sun Apr 30 15:27:39 CST 2023, time=2023-04-30, status=1, ipAttribution=上海)]
    2023-11-20 ms7000000914996124 来自四川省

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2145282, encodeId=6244214528220, content=审稿速度:4.0<br>偏重的研究方向:临床医学<br>经验分享:cell新子刊,看近期的文章质量,往20分去的。有幸中了一篇,历时7个月,本人肿瘤方向,主要做的临床样本和机制。前期慢的都想溜了,还好耐心等下去了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48ef2508535, createdName=yo3333, createdTime=Wed Jun 28 22:27:14 CST 2023, time=2023-06-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2138810, encodeId=3dbf2138810b5, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤免疫<br>经验分享:首个影响因子很高,仔细分析发现,引用次数前十的都是新冠相关的研究,预计最近两年的影响因子将持续下滑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=DDPP, createdTime=Wed May 24 13:49:22 CST 2023, time=2023-05-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2181986, encodeId=5e5b21819861b, content=想问一下,pre-accept之后大概多久发proof啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64935318954, createdName=尤文化, createdTime=Tue Jan 16 15:46:02 CST 2024, time=2024-01-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2177325, encodeId=e95a21e732597, content=审稿速度:24.0 | 投稿命中率:5.0<br>偏重的研究方向:肿瘤<br>经验分享:投稿1年,数次修回,暂无进展。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7d361735891, createdName=ITALIAN, createdTime=Tue Dec 26 16:46:22 CST 2023, time=2023-12-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2173652, encodeId=c0a321e36528e, content=cell转投,转投三天了,还没分配编辑和稿号,这正常吗?请问大佬们有没有遇到过这样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ab745477244, createdName=xiaozou_up20, createdTime=Fri Dec 08 09:10:48 CST 2023, time=2023-12-08, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2169679, encodeId=968821696e98f, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59f79071994, createdName=ms7000000914996124, createdTime=Mon Nov 20 10:11:48 CST 2023, time=2023-11-20, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2118459, encodeId=00542118459f1, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:请教下,修回后一般多久有消息啊?还送外审么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a302426205, createdName=123a7f4dm47暂无昵称, createdTime=Thu Mar 09 10:31:00 CST 2023, time=2023-03-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1213677, encodeId=475b12136e7ee, content=审稿两个月了,希望能给个修回。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=27, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210104/1a4d3d11af7842afadd172a4a59b32f9/66b07e825e8e4455b5099c678c51e0c6.jpg, createdBy=ab332214260, createdName=susu2019, createdTime=Sat Apr 23 15:06:58 CST 2022, time=2022-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145332, encodeId=8473214533219, content=2023年14.3分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:40:51 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2129432, encodeId=85e32129432bc, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=682b8647575, createdName=ms5000001932404434, createdTime=Sun Apr 30 15:27:39 CST 2023, time=2023-04-30, status=1, ipAttribution=上海)]
    2023-03-09 123a7f4dm47暂无昵称 来自上海

    审稿速度:2.0 | 投稿命中率:25.0
    经验分享:请教下,修回后一般多久有消息啊?还送外审么?

    7

    展开7条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=2145282, encodeId=6244214528220, content=审稿速度:4.0<br>偏重的研究方向:临床医学<br>经验分享:cell新子刊,看近期的文章质量,往20分去的。有幸中了一篇,历时7个月,本人肿瘤方向,主要做的临床样本和机制。前期慢的都想溜了,还好耐心等下去了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48ef2508535, createdName=yo3333, createdTime=Wed Jun 28 22:27:14 CST 2023, time=2023-06-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2138810, encodeId=3dbf2138810b5, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤免疫<br>经验分享:首个影响因子很高,仔细分析发现,引用次数前十的都是新冠相关的研究,预计最近两年的影响因子将持续下滑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=DDPP, createdTime=Wed May 24 13:49:22 CST 2023, time=2023-05-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2181986, encodeId=5e5b21819861b, content=想问一下,pre-accept之后大概多久发proof啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64935318954, createdName=尤文化, createdTime=Tue Jan 16 15:46:02 CST 2024, time=2024-01-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2177325, encodeId=e95a21e732597, content=审稿速度:24.0 | 投稿命中率:5.0<br>偏重的研究方向:肿瘤<br>经验分享:投稿1年,数次修回,暂无进展。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7d361735891, createdName=ITALIAN, createdTime=Tue Dec 26 16:46:22 CST 2023, time=2023-12-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2173652, encodeId=c0a321e36528e, content=cell转投,转投三天了,还没分配编辑和稿号,这正常吗?请问大佬们有没有遇到过这样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ab745477244, createdName=xiaozou_up20, createdTime=Fri Dec 08 09:10:48 CST 2023, time=2023-12-08, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2169679, encodeId=968821696e98f, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59f79071994, createdName=ms7000000914996124, createdTime=Mon Nov 20 10:11:48 CST 2023, time=2023-11-20, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2118459, encodeId=00542118459f1, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:请教下,修回后一般多久有消息啊?还送外审么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a302426205, createdName=123a7f4dm47暂无昵称, createdTime=Thu Mar 09 10:31:00 CST 2023, time=2023-03-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1213677, encodeId=475b12136e7ee, content=审稿两个月了,希望能给个修回。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=27, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210104/1a4d3d11af7842afadd172a4a59b32f9/66b07e825e8e4455b5099c678c51e0c6.jpg, createdBy=ab332214260, createdName=susu2019, createdTime=Sat Apr 23 15:06:58 CST 2022, time=2022-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145332, encodeId=8473214533219, content=2023年14.3分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:40:51 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2129432, encodeId=85e32129432bc, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=682b8647575, createdName=ms5000001932404434, createdTime=Sun Apr 30 15:27:39 CST 2023, time=2023-04-30, status=1, ipAttribution=上海)]
    2022-04-23 susu2019

    审稿两个月了,希望能给个修回。

    27

    展开27条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2145282, encodeId=6244214528220, content=审稿速度:4.0<br>偏重的研究方向:临床医学<br>经验分享:cell新子刊,看近期的文章质量,往20分去的。有幸中了一篇,历时7个月,本人肿瘤方向,主要做的临床样本和机制。前期慢的都想溜了,还好耐心等下去了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48ef2508535, createdName=yo3333, createdTime=Wed Jun 28 22:27:14 CST 2023, time=2023-06-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2138810, encodeId=3dbf2138810b5, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤免疫<br>经验分享:首个影响因子很高,仔细分析发现,引用次数前十的都是新冠相关的研究,预计最近两年的影响因子将持续下滑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=DDPP, createdTime=Wed May 24 13:49:22 CST 2023, time=2023-05-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2181986, encodeId=5e5b21819861b, content=想问一下,pre-accept之后大概多久发proof啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64935318954, createdName=尤文化, createdTime=Tue Jan 16 15:46:02 CST 2024, time=2024-01-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2177325, encodeId=e95a21e732597, content=审稿速度:24.0 | 投稿命中率:5.0<br>偏重的研究方向:肿瘤<br>经验分享:投稿1年,数次修回,暂无进展。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7d361735891, createdName=ITALIAN, createdTime=Tue Dec 26 16:46:22 CST 2023, time=2023-12-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2173652, encodeId=c0a321e36528e, content=cell转投,转投三天了,还没分配编辑和稿号,这正常吗?请问大佬们有没有遇到过这样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ab745477244, createdName=xiaozou_up20, createdTime=Fri Dec 08 09:10:48 CST 2023, time=2023-12-08, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2169679, encodeId=968821696e98f, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59f79071994, createdName=ms7000000914996124, createdTime=Mon Nov 20 10:11:48 CST 2023, time=2023-11-20, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2118459, encodeId=00542118459f1, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:请教下,修回后一般多久有消息啊?还送外审么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a302426205, createdName=123a7f4dm47暂无昵称, createdTime=Thu Mar 09 10:31:00 CST 2023, time=2023-03-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1213677, encodeId=475b12136e7ee, content=审稿两个月了,希望能给个修回。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=27, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210104/1a4d3d11af7842afadd172a4a59b32f9/66b07e825e8e4455b5099c678c51e0c6.jpg, createdBy=ab332214260, createdName=susu2019, createdTime=Sat Apr 23 15:06:58 CST 2022, time=2022-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145332, encodeId=8473214533219, content=2023年14.3分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:40:51 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2129432, encodeId=85e32129432bc, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=682b8647575, createdName=ms5000001932404434, createdTime=Sun Apr 30 15:27:39 CST 2023, time=2023-04-30, status=1, ipAttribution=上海)]
    2023-06-29 侠胆医心 来自香港

    2023年14.3分

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2145282, encodeId=6244214528220, content=审稿速度:4.0<br>偏重的研究方向:临床医学<br>经验分享:cell新子刊,看近期的文章质量,往20分去的。有幸中了一篇,历时7个月,本人肿瘤方向,主要做的临床样本和机制。前期慢的都想溜了,还好耐心等下去了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48ef2508535, createdName=yo3333, createdTime=Wed Jun 28 22:27:14 CST 2023, time=2023-06-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2138810, encodeId=3dbf2138810b5, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤免疫<br>经验分享:首个影响因子很高,仔细分析发现,引用次数前十的都是新冠相关的研究,预计最近两年的影响因子将持续下滑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=DDPP, createdTime=Wed May 24 13:49:22 CST 2023, time=2023-05-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2181986, encodeId=5e5b21819861b, content=想问一下,pre-accept之后大概多久发proof啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64935318954, createdName=尤文化, createdTime=Tue Jan 16 15:46:02 CST 2024, time=2024-01-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2177325, encodeId=e95a21e732597, content=审稿速度:24.0 | 投稿命中率:5.0<br>偏重的研究方向:肿瘤<br>经验分享:投稿1年,数次修回,暂无进展。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7d361735891, createdName=ITALIAN, createdTime=Tue Dec 26 16:46:22 CST 2023, time=2023-12-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2173652, encodeId=c0a321e36528e, content=cell转投,转投三天了,还没分配编辑和稿号,这正常吗?请问大佬们有没有遇到过这样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ab745477244, createdName=xiaozou_up20, createdTime=Fri Dec 08 09:10:48 CST 2023, time=2023-12-08, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2169679, encodeId=968821696e98f, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59f79071994, createdName=ms7000000914996124, createdTime=Mon Nov 20 10:11:48 CST 2023, time=2023-11-20, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2118459, encodeId=00542118459f1, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:请教下,修回后一般多久有消息啊?还送外审么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a302426205, createdName=123a7f4dm47暂无昵称, createdTime=Thu Mar 09 10:31:00 CST 2023, time=2023-03-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1213677, encodeId=475b12136e7ee, content=审稿两个月了,希望能给个修回。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=27, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210104/1a4d3d11af7842afadd172a4a59b32f9/66b07e825e8e4455b5099c678c51e0c6.jpg, createdBy=ab332214260, createdName=susu2019, createdTime=Sat Apr 23 15:06:58 CST 2022, time=2022-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145332, encodeId=8473214533219, content=2023年14.3分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:40:51 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2129432, encodeId=85e32129432bc, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=682b8647575, createdName=ms5000001932404434, createdTime=Sun Apr 30 15:27:39 CST 2023, time=2023-04-30, status=1, ipAttribution=上海)]
    2023-04-30 ms5000001932404434 来自上海

    0

共69条页码: 1/7页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分